biologic

Menquadfi

Meningococcal (Groups A, C, Y, W) Conjugate Vaccine

Loss of exclusivityApril 2032FDA regulatory exclusivity expiry
CompanySanofi Vaccines US Inc.

Drug detail

Brand nameMenquadfi
Active ingredientMeningococcal (Groups A, C, Y, W) Conjugate Vaccine
Strength0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalApril 2020
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Menquadfi patent cliff — loss of exclusivity April 2032 | CliffBio